Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02834884
Other study ID # EORTC-1553
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 3, 2017
Est. completion date March 2026

Study information

Verified date November 2023
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact EORTC HQ
Phone +32 2 774 1611
Email specta@eortc.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.


Description:

Patients are recruited in the platform for the research purpose of 4 downstream projects. For more information, please have a look at the "Groups and cohorts" section.


Recruitment information / eligibility

Status Recruiting
Enrollment 4975
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility - Patients with pathologically confirmed selected tumor types (at site or centrally); - Mandatory availability of adequate human biological material (HBM); - Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; - Age = 12 years; - Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; - Written informed consent according to applicable legal and ethical requirements;

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
RP-1828 IMMUcan
WES, lcWGS and RNAseq, multiplex IF and IMC
RP-1759 AYA/TYA
WES, RNAseq and EPIC array
RP-1843 Arcagen
NGS panel
RP-1920 BioRadon
NGS panel

Locations

Country Name City State
Austria Medical University Vienna - General Hospital AKH Vienna
Belgium Onze Lieve Vrouw Ziekenhuis Aalst
Belgium ZNA Middelheim Antwerp
Belgium Cliniques Universitaires Saint-Luc Brussels
Belgium Hopitaux Universitaires - Institut Jules Bordet Brussels
Belgium Universitair Ziekenhuis Brussel Brussels
Belgium Universitair Ziekenhuis Gent Gent
Belgium U.Z. Leuven - Campus Gasthuisberg Leuven
Belgium C.H.U. Sart-Tilman Liège
Belgium Centre Hospitalier Regional De La Citadelle Liège
Belgium CHU Site Sainte-Elisabeth-UCL Namur Namur
Belgium AZ Turnhout - Campus Sint Elisabeth Turnhout
Belgium CHU Mont Godinne - UCL Namur Yvoir
Croatia University Hospital Centre Zagreb Zagreb
Cyprus Bank Of Cyprus Oncology Centre Stróvolos
Czechia University Hospital Motol Prague
Estonia North Estonia Medical Centre - Mustamäe unit Tallinn
France Institut de Cancerologie de l'Ouest (ICO) - Centre Paul Papin Angers
France Centre Hospitalier Avignon Avignon
France CHRU de Besancon - Hopital Jean Minjoz Besancon
France Centre de Radiotherapie Pierre Curie Beuvry
France CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre Bordeaux
France Institut Bergonie Bordeaux
France CHU de Lyon - Hopital Louis Pradel Bron
France CHU Lyon - Hopital neurologique Pierre Wertheimer Bron
France Centre Hopitalier Intercommunal De Creteil Creteil
France Centre Georges-Francois-Leclerc Dijon
France CHU de Grenoble - La Tronche - Hôpital A. Michallon Grenoble
France Centre Hospitalier Departemental Vendee La Roche Sur Yon
France Centre Oscar Lambret Lille
France CHRU de Lille Lille
France Centre Léon Berard Lyon
France CHU de Lyon - Hopital Edouard Herriot Lyon
France CHU de Lyon - Hopital Lyon Sud Lyon
France Assistance Publique - Hopitaux de Marseille - Hopital Nord Marseille
France Centre Hospitalier D'Annecy Metz-Tessy
France CHU Montpellier-Hopital Arnaud De Villeneuve Montpellier
France Institut du Cancer de Montpellier Montpellier Cedex 5
France Centre Hospitalier Des Pays De Morlaix Morlaix
France Centre d'Oncologie de Gentilly Nancy
France CHU de Nice - Hopital De L'Archet Nice
France Assistance Publique - Hopitaux de Paris - Hopital Saint Antoine Paris
France Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere Paris
France Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis Paris
France Groupe Hospitalier Paris Saint-Joseph - Hopital Saint Joseph Paris
France Centre Eugene Marquis Rennes
France Clinique Mutualiste de l'Estuaire - Centre d'oncologie Saint Nazaire
France Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau Saint-Herblain
France Institut de Cancerologie de la Loire Lucien Neuwirth Saint-Priest-en-Jarez
France Institut de Cancerologie Strasbourg Europe (formar Paul Strauss) Strasbourg
France CHU Toulouse - Hopital Larrey Toulouse
France Gustave Roussy Villejuif
Germany Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum Berlin
Germany Universitaetsklinikum Carl Gustav Carus Dresden
Germany Universitaetsklinikum Jena Jena
Germany Onkologie UnterEms, Leer-Papenburg-Emden Leer
Greece Athens University - Attikon University General Hospital Athens
Greece Hygeia Hospital Athens
Greece NIMTS - Veterans Administration Hospital Athens
Greece Ioannina University Hospital Ioánnina
Italy Ospedale Civile Santi Antonio e Biagio e Cesare Arrigo Alessandria
Italy Alma Mater Studiorium Universita di Bologna - Loc. Ospedala Sant'Orsolo Bologna
Italy Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia Brescia
Italy Azienda Istituti Ospitalieri di Cremona Cremona
Italy IRCCS Azienda Ospedaliera Universitaria San Martino "IST" Istituto Nazionale per la Ricerca sul Cancro Genova
Italy Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital Legnago
Italy IRCCS - Istituto Neurologico Carlo Besta Milano
Italy Ospedale del Mare Napoli
Italy Universita Di Torino - Ospedale S. Luigi Gonzaga Orbassano
Italy IRCCS - Istituto Oncologico Veneto Padova
Italy Istituti Clinici Scientifici Maugeri Pavia
Italy Regina Elena National Cancer Center Roma
Italy Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale Molinette Torino
Italy Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Giovanni - Dipartimento Neuroscienze Torino
Italy Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale Sant'Anna Torino
Lithuania Lithuanian Oncology Center-Nat. Cancer Inst Vilnius
Netherlands Amsterdam UMC - Locatie AMC Amsterdam
Netherlands The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Amsterdam
Netherlands University Medical Center Groningen Groningen
Netherlands Academisch Ziekenhuis Maastricht Maastricht
Netherlands Radboud University Medical Center Nijmegen Nijmegen
Poland Medical University Of Gdansk Gdansk
Poland Maria S. Curie Memorial Institute-Gliwice Branche Gliwice
Poland The Great Poland Cancer Centre Poznan
Poland Maria Sklodowska-Curie Memorial Cancer Centre Warsaw
Portugal Centro Hospitalar de Lisboa Ocidental- San Francisco Xavier Hospital Lisboa
Portugal Hospital CUF Descobertas Lisboa
Portugal Hospital CUF Tejo Lisboa
Portugal Instituto Portugues de Oncologia de Lisboa Francisco Gentil - EPE Lisboa
Portugal Centro Hospitalar do Porto- Hospital de Santo Antonio Porto
Portugal Instituto Portugues de Oncologia do Porto Porto
Portugal Cen.Hospitalar Vila Nova Gaia Vila Nova De Gaia
Romania Medisprof Cancer Center srl Cluj Cluj Napoca
Serbia University Clinic Centre Serbia - Pulmonoloy clinic Belgrade
Serbia University Clinical Center of Serbia - Clinic for ENT and MFH Belgrade
Slovenia University Clinic Golnik Golnik
Slovenia University Medical Center Maribor Maribor
Spain Hospital Clinic Universitari de Barcelona Barcelona
Spain Hospital De La Santa Creu I Sant Pau Barcelona
Spain Vall d'Hebron Institut d'Oncologia Barcelona
Spain Hospital General Universitario De Elche Elche
Spain ICO Girona - Hospital Doctor Josep Trueta (Institut Catala D'Oncologia) Girona
Spain ICO L'Hospitalet- Hospital Universitari de Bellvitge L'Hospitalet De Llobregat
Spain Hospital Infantil Universitario Nino Jesus Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Infanta Leonor Madrid
Spain Hospital Universitario QuironSalud Madrid
Spain Hospital Universitario Ramon y Cajal Madrid
Spain Hospital Universitario San Carlos Madrid
Spain Hospital Universitario Virgen De La Victoria Malaga
Spain Hospital Clinico Universitario De Valencia Valencia
Spain Hospital Clinico Universitaro De Valladolid Valladolid
Switzerland Hirslanden Klinik-Tumor Zentrum Aarau Aarau
Switzerland Kantonsspital St Gallen Saint Gallen
Switzerland UniversitaetsSpital Zurich Zurich
Switzerland UniversitaetsSpital Zurich - Neurology Clinic Zurich
United Kingdom Royal Orthopaedics Hospital, NHS Trust Birmingham
United Kingdom University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre Birmingham
United Kingdom Betsi Cadwaladr University Health Board - Glan Clwyd District General Hospital Bodelwyddan Denbighshire
United Kingdom Cambridge University Hospital NHS - Addenbrookes Hospital Cambridge
United Kingdom Velindre NHS Trust - Velindre Cancer Centre Cardiff
United Kingdom University Hospitals Coventry and Warwickshire NHS Trust - University Hospital Coventry
United Kingdom NHS Lothian - Western General Hospital Edinburgh
United Kingdom NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital Glasgow
United Kingdom Hereford County Hospital Hereford
United Kingdom Leeds Teaching Hospitals NHS Trust - St. James's University Hospital Leeds
United Kingdom Royal Free Hospital London
United Kingdom The Christie NHS Foundation Trust Manchester

Sponsors (1)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Countries where clinical trial is conducted

Austria,  Belgium,  Croatia,  Cyprus,  Czechia,  Estonia,  France,  Germany,  Greece,  Italy,  Lithuania,  Netherlands,  Poland,  Portugal,  Romania,  Serbia,  Slovenia,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care. 5 years
Secondary To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future; 5 years
Secondary To investigate the molecular pathways related to the development of specific tumors from a biological point of view; 5 years
Secondary To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally; 5 years
Secondary To collect large series of homogeneous clinical data to analyse the disease course and treatment performed; 5 years
Secondary To investigate the prevalence and validate the prognostic or predictive value of novel biomarkers in cancers; 5 years
Secondary To perform biospecimen and data based high quality research aiming to facilitate the discovery of new test for tumor biomarkers or facilitate the establishment of validated tests for tumor biomarkers; 5 years
Secondary To identify patients with molecular alterations in their tumor that can be matched to biomarker-driven clinical trials, to facilitate enrollment of cancer patients in biomarker-driven clinical trials. 5 years